{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:04:34Z","timestamp":1785769474622,"version":"3.56.0"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Beh\u00e7et\u2019s disease (BD) is characterized by relapsing mucocutaneous and major organ involvement. Although conventional immunosuppressants and CSs remain the mainstay of therapy, severe or refractory cases often require biologics. TNF-\u03b1 inhibitors, particularly infliximab (IFX) and adalimumab (ADA), have become central to BD management. We compared the efficacy, safety, and drug retention of IFX and ADA in a real-world single-centre cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eighty-seven BD patients receiving IFX (n\u2009=\u200945) or ADA (n\u2009=\u200942) as their first anti-TNF therapy between April 2020 and 2025 were retrospectively reviewed. Baseline demographics, organ involvement, laboratory parameters, treatment regimens, and outcomes were recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Except for a tendency of male predominance in the IFX group, baseline demographics were comparable. Vascular (51.1% vs 26.2%) and neurological (15.6% vs 2.4%) involvement were more frequent in the IFX group, while ocular disease predominated in the ADA group (45.2% vs 28.9%). Complete remission was achieved in 75.6% (IFX) and 78.6% (ADA) initially, increasing to 88.9% and 76.5%, respectively, at the last visit. Concomitant AZA use exceeded 60% in both groups, while pulse glucocorticoids, CYC, and anticoagulants were more common with IFX. Relapses occurred more often and earlier with IFX (37.8% vs 16.7%, median 8 vs 13\u2009months). Drug retention and adverse event rates were comparable (IFX 80% vs ADA 85.7%; \u223c16% adverse events). No severe events occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Both IFX and ADA were highly effective and well tolerated in severe or refractory BD. ADA provided durable control in mucocutaneous and ocular phenotypes, whereas IFX offered rapid remission in vascular and neurological disease. Phenotype-oriented and individualized treatment strategies may optimize anti-TNF use in BD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keag021","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T12:28:03Z","timestamp":1768307283000},"source":"Crossref","is-referenced-by-count":3,"title":["Tumor necrosis factor alpha inhibitors in Beh\u00e7et\u2019s disease: indications, efficacy, and safety of two widely used agents"],"prefix":"10.1093","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4537-894X","authenticated-orcid":false,"given":"Rabia","family":"Deniz","sequence":"first","affiliation":[{"name":"Department of Rheumatology, University of Health Sciences Ba\u015fak\u015fehir \u00c7am and Sakura City Hospital , Istanbul,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4579-7062","authenticated-orcid":false,"given":"Oya","family":"Altun","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Health Sciences Ba\u015fak\u015fehir \u00c7am and Sakura City Hospital , Istanbul,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5055-8491","authenticated-orcid":false,"given":"Saliha","family":"Kasapo\u011flu Erdil","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Health Sciences Ba\u015fak\u015fehir \u00c7am and Sakura City Hospital , Istanbul,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4306-3349","authenticated-orcid":false,"given":"Fat\u0131ma G\u00fcl G\u00fclbah\u00e7e","family":"\u0130ncesu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Health Sciences Ba\u015fak\u015fehir \u00c7am and Sakura City Hospital , Istanbul,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1730-2991","authenticated-orcid":false,"given":"Cemal","family":"Bes","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Health Sciences Ba\u015fak\u015fehir \u00c7am and Sakura City Hospital , Istanbul,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"2026021205271563500_keag021-B1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/1568010053622894","article-title":"Behcet\u2019s disease as an autoinflammatory disorder","volume":"4","author":"Gul","year":"2005","journal-title":"Curr Drug Targets Inflamm Allergy"},{"key":"2026021205271563500_keag021-B2","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.rdc.2023.03.010","article-title":"Behcet Syndrome","volume":"49","author":"Hatemi","year":"2023","journal-title":"Rheum Dis Clin North Am"},{"key":"2026021205271563500_keag021-B3","doi-asserted-by":"crossref","first-page":"106868","DOI":"10.1016\/j.jsbmb.2025.106868","article-title":"Potential contribution of oxysterols and cholestanol in the vascular inflammatory process occurring in patients with Behcet\u2019s disease","volume":"255","author":"Messedi","year":"2026","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2026021205271563500_keag021-B4","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1093\/rheumatology\/key242","article-title":"Management of major organ involvement of Behcet\u2019s syndrome: a systematic review for update of the EULAR recommendations","volume":"57","author":"Ozguler","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2026021205271563500_keag021-B5","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018 update of the EULAR recommendations for the management of Behcet\u2019s syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2026021205271563500_keag021-B6","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1097\/RHU.0000000000002146","article-title":"Cytokine signature differences in major phenotypic groups of behcet disease","volume":"30","author":"Deniz","year":"2024","journal-title":"J Clin Rheumatol"},{"key":"2026021205271563500_keag021-B7","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1080\/08820139.2017.1306865","article-title":"Th17-\u0131nducing conditions lead to in vitro activation of both Th17 and Th1 responses in Behcet\u2019s disease","volume":"46","author":"Deniz","year":"2017","journal-title":"Immunol Invest"},{"key":"2026021205271563500_keag021-B8","first-page":"CD005468","article-title":"TNF-alpha inhibitors for ankylosing spondylitis","volume":"2015","author":"Maxwell","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2026021205271563500_keag021-B9","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s40265-023-01916-2","article-title":"Anti-TNF agents and new biological agents (vedolizumab and ustekinumab) in the prevention and treatment of postoperative recurrence after surgery in Crohn\u2019s disease","volume":"83","author":"Gisbert","year":"2023","journal-title":"Drugs"},{"key":"2026021205271563500_keag021-B10","doi-asserted-by":"crossref","first-page":"17562848211070940","DOI":"10.1177\/17562848211070940","article-title":"Systematic review and meta-analysis: evaluating response to empiric anti-TNF dose intensification for secondary loss of response in Crohn\u2019s disease","volume":"15","author":"Srinivasan","year":"2022","journal-title":"Therap Adv Gastroenterol"},{"key":"2026021205271563500_keag021-B11","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1080\/09273948.2025.2479802","article-title":"Effectiveness of frequently used TNF \u0131nhibitors vs. conventional \u0131mmunosuppressive therapies for noninfectious uveitis","volume":"33","author":"Gangaputra","year":"2025","journal-title":"Ocul Immunol Inflamm"},{"key":"2026021205271563500_keag021-B12","first-page":"1078","article-title":"Criteria for diagnosis of Behcet\u2019s disease. International Study Group for Behcet\u2019s Disease","volume":"335","year":"1990","journal-title":"Lancet"},{"key":"2026021205271563500_keag021-B13","doi-asserted-by":"crossref","first-page":"ii51","DOI":"10.1136\/ard.61.suppl_2.ii51","article-title":"Behcet\u2019s disease: a new target for anti-tumour necrosis factor treatment","volume":"61 Suppl 2","author":"Sfikakis","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"2026021205271563500_keag021-B14","first-page":"1045","article-title":"Behcet\u2019s disease: from hippocrates to TNF-alpha-blockers","volume":"4","author":"Zuber","year":"2008","journal-title":"Rev Med Suisse"},{"key":"2026021205271563500_keag021-B15","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s11739-018-1991-y","article-title":"Vascular Behcet\u2019s syndrome: an update","volume":"14","author":"Emmi","year":"2019","journal-title":"Intern Emerg Med"},{"key":"2026021205271563500_keag021-B16","doi-asserted-by":"crossref","first-page":"EVIDoa2300354","DOI":"10.1056\/EVIDoa2300354","article-title":"Infliximab versus cyclophosphamide for severe Behcet\u2019s syndrome","volume":"3","author":"Saadoun","year":"2024","journal-title":"NEJM Evid"},{"key":"2026021205271563500_keag021-B17","doi-asserted-by":"crossref","first-page":"e3863","DOI":"10.1097\/MD.0000000000003863","article-title":"Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study","volume":"95","author":"Hibi","year":"2016","journal-title":"Medicine (Baltimore"},{"key":"2026021205271563500_keag021-B18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11940-016-0405-6","article-title":"Behcet\u2019s disease and nervous system \u0131nvolvement","volume":"18","author":"Kurtuncu","year":"2016","journal-title":"Curr Treat Options Neurol"},{"key":"2026021205271563500_keag021-B19","doi-asserted-by":"crossref","first-page":"e3550","DOI":"10.1097\/MD.0000000000003550","article-title":"Efficacy of anti-TNFalpha in severe and refractory neuro-behcet disease: an observational study","volume":"95","author":"Desbois","year":"2016","journal-title":"Medicine (Baltimore"},{"key":"2026021205271563500_keag021-B20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/BOR.0000000000000911","article-title":"Uveitis in Behcet disease\u2014an update","volume":"35","author":"Tugal-Tutkun","year":"2023","journal-title":"Curr Opin Rheumatol"},{"key":"2026021205271563500_keag021-B21","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10067-016-3480-x","article-title":"Efficacy and safety of adalimumab in Behcet\u2019s disease-related uveitis: a multicenter retrospective observational study","volume":"36","author":"Fabiani","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2026021205271563500_keag021-B22","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1136\/ard-2024-226113","article-title":"Efficacy and safety of infliximab or adalimumab in severe mucocutaneous Behcet\u2019s syndrome refractory to traditional immunosuppressants: a 6-month, multicentre, randomised controlled, prospective, parallel group, single-blind trial","volume":"84","author":"Talarico","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2026021205271563500_keag021-B23","first-page":"S54","article-title":"Efficacy of adalimumab in patients with Behcet\u2019s disease unsuccessfully treated with infliximab","volume":"29(Suppl 67)","author":"Olivieri","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"2026021205271563500_keag021-B24","doi-asserted-by":"crossref","first-page":"e15096","DOI":"10.1111\/1756-185X.15096","article-title":"Long-term efficacy, safety, and cumulative retention rate of antitumor necrosis factor-alpha treatment for patients with Behcet\u2019s uveitis: a systematic review and meta-analysis","volume":"27","author":"Guan","year":"2024","journal-title":"Int J Rheum Dis"},{"key":"2026021205271563500_keag021-B25","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/09273948.2017.1391297","article-title":"Ten-Year Retention Rate of Infliximab in Patients with Behcet\u2019s Disease-Related Uveitis","volume":"27","author":"Fabiani","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"key":"2026021205271563500_keag021-B26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/1756-185X.12732","article-title":"Safety profile of biologic agents for Behcet\u2019s disease in a multicenter observational cohort study","volume":"20","author":"Cantarini","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"2026021205271563500_keag021-B27","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1002\/art.41026","article-title":"Comparative study of \u0131nfliximab versus adalimumab in refractory uveitis due to Behcet\u2019s disease: national multicenter study of 177 cases","volume":"71","author":"Atienza-Mateo","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2026021205271563500_keag021-B28","doi-asserted-by":"crossref","first-page":"17562848221116666","DOI":"10.1177\/17562848221116666","article-title":"Anti-TNF-alpha agents for refractory intestinal Behcet\u2019s disease: case series and meta-analysis","volume":"15","author":"Zhan","year":"2022","journal-title":"Therap Adv Gastroenterol"},{"key":"2026021205271563500_keag021-B29","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13075-019-1933-8","article-title":"Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet\u2019s disease","volume":"21","author":"Miyagawa","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2026021205271563500_keag021-B30","first-page":"S58","article-title":"Adalimumab for treatment of severe Behcet\u2019s uveitis: a retrospective long-term follow-up study","volume":"32","author":"Interlandi","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2026021205271563500_keag021-B31","doi-asserted-by":"crossref","first-page":"22227","DOI":"10.1038\/s41598-020-78718-z","article-title":"A 10-year follow-up of infliximab monotherapy for refractory uveitis in Behcet\u2019s syndrome","volume":"10","author":"Horiguchi","year":"2020","journal-title":"Sci Rep"},{"key":"2026021205271563500_keag021-B32","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/rheumatology\/keq031","article-title":"Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents","volume":"49","author":"Horiuchi","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"2026021205271563500_keag021-B33","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cyto.2008.11.008","article-title":"Differences in binding and effector functions between classes of TNF antagonists","volume":"45","author":"Arora","year":"2009","journal-title":"Cytokine"},{"key":"2026021205271563500_keag021-B34","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/art.23447","article-title":"Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab","volume":"58","author":"Mitoma","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2026021205271563500_keag021-B35","doi-asserted-by":"crossref","first-page":"27059","DOI":"10.1074\/jbc.M113.491530","article-title":"Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor alpha-associated diseases from a molecular view","volume":"288","author":"Hu","year":"2013","journal-title":"J Biol Chem"},{"key":"2026021205271563500_keag021-B36","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/rheumatology\/ket260","article-title":"The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases","volume":"53","author":"Jani","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"2026021205271563500_keag021-B37","doi-asserted-by":"crossref","first-page":"S521","DOI":"10.4103\/IJO.IJO_2011_23","article-title":"Comparative results of use and switching of anti-TNF-alpha agents in adult Behcet\u2019s uveitis","volume":"72","author":"Mesen","year":"2024","journal-title":"Indian J Ophthalmol"},{"key":"2026021205271563500_keag021-B38","first-page":"101","article-title":"Indications, response, and side effects of biologic treatment in Behcet\u2019s disease: an 8-year study with follow-up","volume":"62","author":"Shenavandeh","year":"2024","journal-title":"Reumatologia"},{"key":"2026021205271563500_keag021-B39","first-page":"611","article-title":"Adalimumab in the management of Behcet\u2019s disease","volume":"11","author":"Ueda","year":"2015","journal-title":"Ther Clin Risk Manag"},{"key":"2026021205271563500_keag021-B40","doi-asserted-by":"crossref","first-page":"4476","DOI":"10.1007\/s12325-024-02993-9","article-title":"Real-world safety and effectiveness of \u0131nfliximab in 255 patients with \u0131ntestinal, neurological, and vascular Behcet\u2019s disease: a post-marketing surveillance","volume":"41","author":"Hibi","year":"2024","journal-title":"Adv Ther"},{"key":"2026021205271563500_keag021-B41","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/s12876-023-03090-x","article-title":"Effectiveness and safety of adalimumab in patients with intestinal Behcet\u2019s disease: a real-world prospective observational study in South Korea","volume":"23","author":"Yu","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"2026021205271563500_keag021-B42","doi-asserted-by":"crossref","first-page":"451675","DOI":"10.1155\/2015\/451675","article-title":"Mucocutaneous \u0131nvolvement in Behcet\u2019s disease: how systemic treatment has changed in the last decades and future perspectives","volume":"2015","author":"Rotondo","year":"2015","journal-title":"Mediators Inflamm"},{"key":"2026021205271563500_keag021-B43","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.2169\/internalmedicine.4705-20","article-title":"Recommendations for the management of neuro-Behcet\u2019s disease by the Japanese National Research Committee for Behcet\u2019s disease","volume":"59","author":"Hirohata","year":"2020","journal-title":"Intern Med"},{"key":"2026021205271563500_keag021-B44","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1345\/aph.1L077","article-title":"Azathioprine-induced warfarin resistance","volume":"42","author":"Vazquez","year":"2008","journal-title":"Ann Pharmacother"},{"key":"2026021205271563500_keag021-B45","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2165\/00063030-200115010-00003","article-title":"Potential new therapeutic options in Behcet\u2019s syndrome","volume":"15","author":"Russell","year":"2001","journal-title":"BioDrugs"},{"key":"2026021205271563500_keag021-B46","first-page":"S64","article-title":"Mycophenolate mofetil as a novel immunosuppressant in the treatment of neuro-Behcet\u2019s disease with parenchymal involvement: presentation of four cases","volume":"29","author":"Shugaiv","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"2026021205271563500_keag021-B47","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/BOR.0000000000000458","article-title":"A review of current management of vasculo-Behcet\u2019s","volume":"30","author":"Merashli","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"2026021205271563500_keag021-B48","first-page":"1799","article-title":"Assessing the efficacy of anticoagulation therapy in the treatment of vascular Behcet\u2019s disease: a systematic review","volume":"43","author":"Omar","year":"2025","journal-title":"Clin Exp Rheumatol"},{"key":"2026021205271563500_keag021-B49","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004943","article-title":"Anticoagulation in venous thromboembolism in Behcet\u2019s syndrome: friend or foe?","volume":"10","author":"Casto","year":"2024","journal-title":"RMD Open"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keag021\/66403720\/keag021.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/2\/keag021\/66403720\/keag021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/2\/keag021\/66403720\/keag021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T10:27:28Z","timestamp":1770892048000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/doi\/10.1093\/rheumatology\/keag021\/8424944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,4]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keag021","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,13]]},"article-number":"keag021"}}